Recent research have centered on the intersection of GLP-1|GIP|glucagon receptor activator therapies and DA neurotransmission. While GLP stimulators are commonly employed for addressing type 2 T2DM, their potential effects on reinforcement circuits, specifically mediated by DA pathways, are gaini